Free Trial
→ Don't lose access to this (From TradeWins) (Ad)tc pixel
NASDAQ:MDWD

MediWound Q3 2026 Earnings Date & Estimates

MediWound logo
$14.20 +0.81 (+6.05%)
Closing price 11/4/2026 04:00 PM Eastern
Extended Trading
$14.19 -0.01 (-0.07%)
As of 04:56 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MediWound is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from MediWound in Q3 2026

MediWound is expected to post earnings of -$0.7067 per share on revenue of $6.73 million. In the same quarter a year earlier MediWound reported -$0.24 per share on revenue of $5.43 million. MediWound last reported on August 13, 2026, posting -$0.77 per share and missing the -$0.7617 consensus estimate. MediWound has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.7067
Expected Revenue
$6.73 million
Prior-Year EPS
-$0.24
Prior-Year Revenue
$5.43 million
Expected Revenue Growth
+23.9%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.77 (Missed by -$0.0083)
Last Quarter Revenue
$3.09 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

MediWound Q3 2026 Earnings FAQ

MediWound (NASDAQ:MDWD) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

MediWound's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect MediWound to post earnings of -$0.7067 per share for Q3 2026.

The consensus revenue estimate for MediWound is $6.73 million for Q3 2026.

MediWound Earnings Headlines

MediWound Prices $15 Mln Offering Of Shares At $12.50 Per Share; Stock Down
November 3 at 10:47 PM  |  rttnews.comhttps://www.rttnews.com/3709035/mediwound-prices-15-mln-offering-of-shares-at-12-50-per-share-stock-down.aspx
MediWound announces $15M public offering of ordinary shares
November 3 at 5:46 PM  |  msn.comhttps://www.msn.com/en-us/news/other/mediwound-announces-15m-public-offering-of-ordinary-shares/ar-AA2gGnQF
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
November 5 at 1:00 AM  |  Weiss Ratings (Ad)
MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares
November 3 at 4:40 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/03/3394850/30505/en/mediwound-announces-15-million-bought-deal-offering-of-ordinary-shares.html
MediWound to Report Third Quarter 2026 Financial Results
October 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/29/3391197/30505/en/mediwound-to-report-third-quarter-2026-financial-results.html
H.C. Wainwright Remains a Buy on Mediwound (MDWD)
October 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MDWD/pressreleases/4930103/hc-wainwright-remains-a-buy-on-mediwound-mdwd/
See More MediWound Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MediWound? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MediWound and other key companies, straight to your email.

About MediWound

MediWound (NASDAQ:MDWD) (NASDAQ: MDWD) is a commercial-stage biotechnology company focused on developing and marketing innovative enzymatic therapies for complex wounds. The company’s products are designed to support the removal of damaged tissue and improve wound management, with an emphasis on severe burns and hard-to-heal chronic wounds.

MediWound’s lead product, NexoBrid, is a bromelain-based topical biological product used for the enzymatic removal of eschar, or dead tissue, from deep partial-thickness and full-thickness thermal burns. NexoBrid has received regulatory approvals in multiple markets, including the United States, the European Union and Israel. In the United States, the product is commercialized through a partnership with Vericel Corporation.

The company is also developing EscharEx, an investigational enzymatic treatment intended to remove nonviable tissue from chronic wounds, including venous leg ulcers. MediWound was founded in 2001 and is headquartered in Yavne, Israel. Its operations and commercial activities serve healthcare markets in North America, Europe, Israel and other international regions.

View MediWound Profile
Earnings Tools